Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | FBP1 | P09467 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.43 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.43 |
| ▸ | MERTK | Q12866 | 2/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125038 | 0.86 | VCAM1 (0.60) | VCAM1MAPTKDM4EALDH1A1CYP3A4 | |
| SCHEMBL29805549 | 0.86 | VCAM1 (0.60) | VCAM1MAPTKDM4EALDH1A1CYP3A4 | |
| SCHEMBL16952509 | 0.85 | VCAM1 (0.54) | VCAM1MAPTEGFRFBP1KDM4E | |
| SCHEMBL16957308 | 0.85 | VCAM1 (0.54) | VCAM1MAPTEGFRFBP1KAT2B | |
| SCHEMBL2927092 | 0.80 | FBP1 (0.44) | VCAM1MAPTFBP1KDM4EALDH1A1 | |
| SCHEMBL4477143 | 0.80 | VCAM1 (0.70) | VCAM1MAPTCYP3A4KAT2BMERTK | |
| SCHEMBL19639797 | 0.79 | VCAM1 (0.48) | VCAM1MAPTEGFRFBP1ALDH1A1 | |
| SCHEMBL7325804 | 0.78 | MAPT (0.53) | MAPTCYP3A4MERTK | |
| SCHEMBL4385438 | 0.77 | VCAM1 (0.61) | VCAM1MAPTALDH1A1ALOX15KAT2B | |
| 2-Nitrobenzaldehyde SCHEMBL7545807 | 0.76 | FBP1 (0.46) | VCAM1MAPTFBP1ALDH1A1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074921-B2 | Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1443936-A4 | PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUTED-2,3,4,5- TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1443936-A2 | PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUTED-2,3,4,5- TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20030162965-A1 | Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-28 | — | — | US | disclosed |
| WO-2003041658-A2 | PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUTED-2,3,4,5- TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162965-A1 | Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds | GABRA4, GABRA3, GABRA6 | VCAM1 2101/4885MAPT 1538/4885EGFR 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.